At its ongoing genomics forum, narrow-moat Illumina finally gave investors a glimpse of its new product pipeline, which could help it stave off new entrants in its legacy sequencing business. While ...
Illumina, Inc. has announced that researchers from the California Institute of Technology and Stanford University School of Medicine, and the National Heart, Lung, and Blood Institute of the National ...
Expands pharma access to large omics datasets to advance target discovery and drug development SAN DIEGO, Oct. 1, 2025 /PRNewswire/ -- Illumina, Inc. (ILMN) today announced the launch of BioInsight, a ...
Illumina (NASDAQ:ILMN) supports global genomic science as nasdaq futures discussions include advanced life sciences platforms ...
SAN DIEGO, Oct. 15, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that GeneDx, a leader in genetic testing for rare diseases, is piloting Illumina's emerging constellation mapped ...
Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention. SAN DIEGO ...
Agreement grants access to Synaffix patent portfolio related to metal-free click chemistry Technology to be used in Illumina's next-generation sequencing (NGS) products AMSTERDAM, Dec. 4, 2024 ...
Illumina Inc (NASDAQ:ILMN)., a leading player in the genomic sequencing industry, finds itself at a critical juncture as it navigates a shifting competitive landscape and global economic challenges.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback